Questcor Pharmaceuticals — Investor Presentation (June 2010)
31 slides from Questcor Pharmaceuticals's investor presentation, Jun 10, 2010
Slide 1: Questcor June 2010
ene iN QUESTCOR June 2010 NASDAQ: QCOR
Slide 2: Cautionary Statement
2 Cautionary Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performan
Slide 3: Questcor Overview
3 Questcor Overview Flagship product: H.P. Acthar(r) Gel (Acthar) Key markets: Multiple Sclerosis, Infantile Spasms, Nephrotic Syndrome Strategy: grow share in these three markets Financials: profitable, debt-free, $91M in cash, cash flow positive
Slide 4: H.P. Acthar Gel
4 H.P. Acthar(r) Gel Highly purified preparation of adrenocorticotropic hormone (ACTH) Key approved indications: Multiple sclerosis (MS) exacerbations Nephrotic syndrome Significant off-label usage
Slide 5: H.P. Acthar Gel: Significant barriers to entry
5 Natural-source biologic involving 39 amino acid ACTH plus multiple peptide fragments Complex, multi-step manufacturing process involving extensive proprietary know-how Very difficult to reproduce by competitor or generic company H.P. Acthar Gel Significant barriers to entry
Slide 6: Questcor Growth Engine
Questcor Growth Engine Multiple Sclerosis From near zero to over $45M run rate in 24 months $500M+ market with little competition Infantile Spasms FDA approval could help increase Acthar's already leading market share Nephrotic Syndrome On-label market >$1B Pilot sales effort started
Slide 7: Multiple Sclerosis
7 Multiple Sclerosis Neurodegenerative disorder affecting 400,000 people in the US An estimated 200-250,000 exacerbations among MS patients in the US annually Market research indicates 10-20,000+ patients per year are candidates for Acthar treatment $500 million to over $1 billion potential market A
Slide 8: H.P. Acthar Gel and MS
8 H.P. Acthar(r) Gel and MS Acthar indicated for treatment of exacerbations associated with MS Small but growing number of Acthar prescribers Currently <400 out of 2,500 MS specialists Q1 sales^over $45M annualized run rate Significant upside potential
Slide 9: Targeted Selling Effort in MS
Targeted Selling Effort in MS Positioning: for select MS flare patients who ... 9
Slide 10: MS Sales Results - Rxs Filled
MS Sales Results-Rxs Filled Q1 '08 Q2 '08 Q3 '08 Q4 '08 Q1 '09 Q2 '09 Q3 '09 Q4 '09 Q1 '10 East 24 35 50 66 78 125 141 213 232 Paid New Rxs
Slide 11: MS Prescriber Growth
11 MS Prescriber Growth (Based on Shipped Rxs)
Slide 12: MS Rxs Shipped/Paid vs Calls
12 MS Rxs Shipped/Paid vs Calls MS Calls # Rxs
Slide 13: MS Sales Growth History
13 MS Sales Growth History Q1-2010 results Q1-10 new Rxs ^ 197% vs Q109 MS sales now exceed IS sales Repeat patients are now >20% of total MS patients prescribed Acthar Expanded sales force Expanded sales force 4 times in last 2 years Sales increased each time
Slide 14: Infantile Spasms
14 Infantile Spasms Devastating, refractory form of childhood epilepsy Very poor developmental outcome if inadequately treated Not responsive to standard anti-epileptic drugs Ultra-orphan disorder 1,500 to 2,000 patients annually Typically occurs in children less than 2 years old Characterized by "s
Slide 15: H.P. Acthar Gel and IS
15 H.P. Acthar(r) Gel and IS Used by many child neurologists Despite lack of indication for IS Key scientific publications Joint CNS, AAN, AES guidelines (Mackay, et al. 2004) Pivotal clinical trial data (Baram, et al. 1996) Few therapeutic alternatives for IS patients Successful advisory panel 5/6/
Slide 16: Trends in IS Sales
Trends in IS Sales Significant quarterly variability Q1-2010 sales within historic range Acthar currently used to treat 30-50% of IS patients No significant impact from Q409 Sabril launch Major IS symposium at Q409 CNS mtg Reinforced key 1st line role for Acthar in IS treatment
Slide 17: Gain IS indication
17 Gain IS indication Timeline sNDA accepted 12/23/09 Positive Advisory Panel Meeting 5/6/10 PDUFA pending Prepare for Q4 sales launch Gain 7 year orphan exclusivity Ability to actively educate providers on proper Acthar dosing and patient monitoring Potential to increase IS revenue 10-30%
Slide 18: Nephrotic Syndrome: Significant unmet need
18 Nephrotic Syndrome: Significant unmet need Characterized by excessive spilling of protein from the kidney into the urine (proteinuria) Nephrotic-range proteinuria caused by a number of underlying kidney diseases and disorders Membranous nephropathy Lupus nephritis Focal segmental glomerular scler
Slide 19: Nephrotic Syndrome: Sizable market for Acthar
19 Nephrotic Syndrome: Sizable market for H.P. Acthar(r) Gel H.P. Acthar(r) Gel is indicated ... To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus Leading nephrologists very supportive of possible use
Slide 20: Case Study: Acthar in Nephrotic Syndrome
Case Study: Acthar in Nephrotic Syndrome 58 year old white male with ESRD due to idiopathic membranous nephropathy Underwent kidney transplant approximately 5 years ago, and has done very well to date Patient history includes post-transplant Diabetes Mellitus, HBV & HCV infection, and coronary arter
Slide 21: Case Study: Acthar in Nephrotic Syndrome
Case Study: Acthar in Nephrotic Syndrome Noted "new bubbles" in his urine* 24-hr urine protein 4851 mg (previously <200 mg) Biopsy performed one month later Mild thickening detected in the glomerular basement membrane of the transplanted kidney Diagnosis >> nephrotic syndrome due to membranous nephr
Slide 22: Case Study: Acthar in Nephrotic Syndrome
Case Study: Acthar in Nephrotic Syndrome Labs before Acthar 24-hr urine 4851 mg/day protein >>> Acthar treatment initiated Labs -- 4 weeks after starting Acthar (40U twice weekly) 24-hr urine 3757 mg/day protein Labs -- 8 weeks after starting Acthar (80U twice weekly) 24-hr urine 1332 mg/day Labs --
Slide 23: Immediate Acthar Growth Opportunities
23 Immediate Acthar Growth Opportunities MS--Build on sales momentum IS--Grow market share after obtaining FDA approval NS--Pursue Nephrotic Syndrome as new therapeutic use; expand pilot sales effort
Slide 24: Financials
24 Financials Profitable, debt free, and cash flow positive
Slide 25: Quarterly Results
25 Quarterly Results Quarterly Results
Slide 26: Q1 2010 Analysis
Q1 2010 Analysis MS sales up 197% YOY IS sales within historic range Modest set of nephrotic syndrome Rxs Solid profitability and cash generation
Slide 27: Balance Sheet
27 Balance Sheet ~ $1.47/share in cash 06/04/10 Cash/ST Investments $91M* Accounts Receivable $14M *After return of $67 million of cash to shareholders through share repurchases. QUESTCOR IS CASH FLOW POSITIVE
Slide 28: Share repurchases
28 Share repurchases: 14 Million shares in 2008-2009 2.2 Million Preferred share buyback 12.4 Common share buyback $67 million returned to shareholders in stock buybacks 62 million shares currently outstanding 5.1 million shares remain on buyback authorization REPURCHASES SIGNIFICANTLY IMPROVE EPS
Slide 29: Go Forward Plan - Sell More Acthar
Go Forward Plan- Sell More Acthar Expand Sales Force to pursue MS, IS and NS markets Approximately double the sales team by Q4 Focus on Acthar Develop other markets for Acthar Acthar is its own pipeline with many possible other therapeutic uses Suspend business development efforts
Slide 30: Investment Highlights
30 Investment Highlights Questcor is streamlined, focused & profitable H.P. Acthar(r) Gel has sustainable competitive advantages Substantial growth in MS sales Significant upside with NS (on-label) Market sizes have good growth potential Cash flow positive/no debt Significant sales expansion program
Slide 31: Questcor June 2010
ene iN QUESTCOR June 2010 NASDAQ: QCOR
Questcor Pharmaceuticals — Investor Presentation (June 2010) on 6ix